Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam's Overshadowed Givosiran Comes Into The Phase III Light

Executive Summary

While attention has been focused on other products, Alnylam is set to take another RNAi product candidate – givosiran – into pivotal testing following positive early data in acute hepatic porphyria.

You may also be interested in...



Alnylam Will Seek Early Approval, But Givosiran Likely To Reach Market Later

Alnylam reported interim Phase III results that it believes support a filing for accelerated approval and a rapid market entry, but a US FDA decision may be delayed by up to six months to allow for a bigger dataset and complete safety assessment in acute hepatic porphyria.

Key Drug Launches To Plan For In 2019

Around three dozen key late-stage products could reach their first markets in 2019, according to a recent report from Informa Pharma's Biomedtracker. Company execs may need to plan for the disruptive potential of this group of new medicines on established markets and standards of care.

Ionis Touts Inotersen's Convenience As Phase III Safety Data Disappoints

Although inotersen met efficacy endpoints in Phase III familial amyloidosis study, adverse event rates raised a red flag and give Alnylam's competing patisiran an edge on safety, at least for now.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

WI964844

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel